Results 111 to 120 of about 3,601 (174)

KLF13-mediated CES2 upregulation via p300-dependent acetylation sensitizes gastric cancer cells to irinotecan. [PDF]

iScience
Zhang HB, Hu RH, Zhang KH, Cui XM, Zhang S.   +4 more
europepmc   +1 more source

Irinotecan Hydrochloride (CPT-11) in Dialysis Patients with Gastrointestinal Cancer

Irinotecan Hydrochloride (CPT-11) in Dialysis Patients with Gastrointestinal Cancer
We investigated changes in drug disposition and toxicities with CPT-11 in 15 dialysis patients with gastrointestinal cancers to clarify whether CPT-11 could be administered safely in such patients. For comparison, the same parameters were also investigated in 10 cancer patients not undergoing dialysis.
openaire  

UGT1A1/ABCC2 AND PHARMACOKINETICS OF IRINOTECAN HYDROCHLORIDE

Abstracts of Annual meeting of Japanese Society for the Study of Xenobiotics, 2008
openaire   +1 more source

Analysis of Bevacizumab-Induced Gastrointestinal Perforation Using the Japanese Adverse Drug Event Report Database. [PDF]

Cureus
Sugishita K, Maezawa M, Miyasaka K, Hirofuji S, Yamashita M, Nokura Y, Ichihara N, Nakao S, Tanaka H, Yamazaki T, Nonomura K, Tamaki H, Iguchi K, Nakamura M.   +13 more
europepmc   +1 more source

Decision-Making Process of Older Adults with Advanced Cancer Regarding Continuation of Systemic Therapy. [PDF]

Glob Qual Nurs Res
Hirayama K.
europepmc   +1 more source

Butyrate prevents chemotherapy-induced gastrointestinal toxicity and microbial dysbiosis. [PDF]

Sci Rep
Cheatham SM, Rehman Z, Arastonejad M, Kane R, Ahmad N, Luffman N, Harada H, Zhang Y, Tyc KM, Gewirtz DA, Akbarali HI.   +10 more
europepmc   +1 more source

A phase I study of liposomal Irinotecan (ONIVYDE®) in combination with TAS-102 (LONSURF®) in refractory solid tumors. [PDF]

Invest New Drugs
Chiang NJ, Bai LY, Ho IW, Hsu CH, Liang YH, Chiu CF, Lin CC, Chang KY, Chen SH, Tsai HJ, Lin YP, Chen LT, Lin CC.   +12 more
europepmc   +1 more source

Phase II study of maintenance trifluridine/tipiracil (TAS-102) plus bevacizumab after induction chemotherapy in metastatic colorectal cancer. [PDF]

Oncologist
Ota K, Uemura M, Tanida T, Nakata K, Kudo T, Kagawa Y, Haraguchi N, Minami S, Matsuura Y, Ota H, Hiraki M, Yasui M, Takahashi H, Iwamoto K, Nishida N, Hata T, Nishizawa Y, Fukunaga M, Komori T, Takahashi Y, Tokuyama S, Tamagawa H, Naito A, Yoshihara T, Suzuki R, Sugimoto S, Miyake M, Takiguchi N, Tei M, Tamai K, Fukada A, Ogino T, Miyoshi N, Satoh T, Yamamoto H, Murata K, Doki Y, Eguchi H.   +37 more
europepmc   +1 more source

NRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in pancreatic cancer. [PDF]

J Natl Cancer Inst
Schram AM, Yang SR, Kahn G, Velasco R, Repetto M, Kinh Gian Do R, DiNapoli S, Sukhadia P, Troxel M, Ozcan K, Tarcan Z, Ladanyi M, Harding JJ, Drilon A, Basturk O, O'Reilly EM.   +15 more
europepmc   +1 more source

The review of topoisomerase I inhibitors: Irinotecan hydrochloride and topotecan hydrochloride for ovarian and cervical cancers.

Japanese Journal of Chemotherapy, 1998
openaire   +1 more source